Ana B. Pavel
University of Mississippi(US)Icahn School of Medicine at Mount Sinai(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Hair Growth and Disorders, IL-33, ST2, and ILC Pathways, Urticaria and Related Conditions
Most-Cited Works
- → A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results(2021)185 cited
- → Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients(2021)134 cited
- → Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality(2021)102 cited
- → Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata(2022)51 cited
- → An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata(2021)44 cited
- → Vascular inflammation in moderate‐to‐severe atopic dermatitis is associated with enhanced Th2 response(2021)43 cited
- → Age of onset defines two distinct profiles of atopic dermatitis in adults(2023)42 cited
- → Mapping atopic dermatitis and anti–IL-22 response signatures to type 2–low severe neutrophilic asthma(2021)33 cited
- → Proteomic characterization of atopic dermatitis blood from infancy to adulthood(2023)31 cited
- → A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis(2021)30 cited